Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Patient centricity is a concept, not a reality

13th World Cancer Congress
February 25-26, 2019 | Paris, France

Nigel Goodman

Gaea OU, Estonia

Posters & Accepted Abstracts : J Med Oncl Ther


Though the industry quoted data on the actual cost of clinical trials is questionable, it’s clear that despite outsourcing to CROs clinical research is too slow and expensive. In cancer specifically, every year multimillions are diagnosed, but only 3-% participate in a clinical trial. For many diseases, a clinical trial could be a patient’s best chance and is accompanied by expert care and a full workup. Patient centricity is a concept, not a reality. Even the FDA state they want trial design to be driven by patients, to make trials less burdensome. Patient diversity is also a priority. Traditional study design still starts from: “How many patients exist that fit these eligibility criteria?” It’s a good starting question, but data that patients exist doesn’t mean they are willing to participate in trials, and we know the common reasons and they can be more pronounced in biosimilar trials. The result of ~3-% being willing to join such trials means trials run slowly. There are hundreds of apps and database access companies, but what effects are they having? A fresh approach is needed.



Get the App